Sequenom Posts 34 Percent Gain in Revenues for Q4; Stock Drops | GenomeWeb

This story has been updated from a previous version to include comments from Sequenom's earnings call.

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its fourth quarter revenues climbed 34 percent from the fourth quarter of 2012, driven by sales of its MaterniT21 Plus test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.